- This event has passed.
Free Webinar: The Investment Journey – Post Covid-19
April 20 @ 10:30 am - 1:00 pm
This webinar, held in association with Hill Dickinson and FRP, will cast light on what the investment climate looks like as a result of the Covid-19 pandemic. It will take you through the investment journey from early-stage investment to floating on the stock exchange, drawing on the experience of investment experts in the Life Sciences sector. Medilink members will also be sharing their practical experience of securing investment.
Who should attend?
CEOs and CFOs of life science businesses of all sizes, academic institutions and NHS organisations involved in technology transfer and product commercialisation.
You will hear from:
Kevin co-founded Medilink in 1997, and is now the Group CEO of Medilink UK and the CEO for Medilink North of England Ltd, a professional association and specialist consultancy for the Life Sciences sector.
With over 30 years’ experience of working across, and catalysing connectivity between, the life science business community, health delivery organisations and academia / technology institutions, Kevin understands the importance of well thought through investment strategies in fast tracking the commercialisation of product / process innovation.
Heath Snyder, Partner, FRP Advisory Group
Heath has more than 25 years’ experience advising companies and working with owner managers, private equity backed companies and listed companies, offering a full spectrum of corporate finance advice. He has extensive experience in mergers and acquisitions, management buyouts, strategic options reviews, debt and equity fund raisings. Heath has also worked in a private equity fund as an investor, sitting on boards of private equity backed companies, and therefore brings a significant understanding of private equity processes and considerations. During his career he has worked in Asia and the United States, helping him specialise in cross-border M&A.
Mark Wyatt, Investment Director, Mercia Asset Management
Mark is an Investment Director with over 18 years’ venture capital experience, with particular expertise in the life science sector. He has been involved in all aspects of creating venture backed businesses, including sourcing new opportunities, working with founders and management teams to build valuable propositions, through to public market listings and trade sales. He has been a non-executive director of several private and public companies. Mark has worked across several early-stage venture funds, including the RisingStars Growth Funds, the North West Fund for Venture Capital, Finance Yorkshire Seedcorm Fund, and is actively looking for new life science deals for the Northern Powerhouse Fund. He has been heavily involved in the following investments; Concepta plc, Evgen and Abingdon Healthcare.
Matt Currie, Investment Director, Seneca Partners Ltd
Matt joined Seneca in 2017 from his previous role in the RBS Structured Finance team where he completed 15 Leverage Finance transactions, being primarily mid-market private equity deals. Working alongside regional private equity firms, Matt led deals across the Leisure/Consumer, TMT, Professional Services, Manufacturing and Infrastructure sectors. Prior to that Matt spent four years with Deloitte, qualifying as a Chartered Accountant and working on both audit and advisory engagements across the North of England. Matt graduated from the University of Manchester in 2010 with a degree in Management with Accounting & Finance and also holds the CFA Investment Management Certificate. Since joining Seneca, Matt has been involved in 26 growth capital transactions totalling more than £25 million providing growth capital to SMEs.
Sam is Chief Executive Officer of LightOx Ltd, a Pharmaceutical development company with a lead asset in Oral Cancer treatment for early stage cancers Sam has a history of working in the medical technologies and commercialisation of scientically developed products, and has successfully raised finance for small businesses he has run throughout his career form investors around the world.
Sam has worked across a range of industrial applications including pharmaceuticals, medical devices, diagnostics, and life sciences. Sam is a also a Royal Society Entrepreneur in Residence, and a Fellow of the Royal Society of Chemistry and a Export Champion for the UK.
Tim Davis, Regional Head of Primary Markets, The London Stock Exchange
Tim joined LSEG in April 2019 and has responsibility for potential AIM and Main Market IPOs across The Midlands, Wales, East Anglia, Cambridge and Oxford. He also has national responsibility for Healthcare.
He spent the previous 25 years working across in UK small and mid-cap advisory and broking roles at Teather & Greenwood, Charles Stanley Securities, Religare Capital Markets and Cantor Fitzgerald Europe.
Jamie Foster, Partner, Hill Dickinson
Jamie is a commercial lawyer specialising in the health and life sciences sectors. Clients include listed healthcare and innovation companies, biotech businesses, NHS organisations involved in R&D and medtech start-ups.
Jamie advises clients on contracting, intellectual property, collaborations, and navigating the commercial and regulatory frameworks for medtech and biotech businesses. He is currently working on collaborations between the NHS and industry relating to data-driven technologies and delivering the digital ambitions of the NHS Long Term Plan.
Jamie is a member of Tech London Advocates (Healthtech group) and frequently presents on life sciences issues for medtech and digital health networking organisations, accelerators and incubators.
Jonathan Gillow, Partner, Hill Dickinson
Jon is a partner in the Manchester corporate team with focus on mergers and acquisitions, public and private equity, and fundraising, Financial Services and Markets Act and joint ventures.
Jon also has experience of acting on partnership and LLP issues, as well as fund formation and alternative investment structures.
Jon's other specialisms include: Business restructuring, Business strategy, Company formation/law/reorganisations; Corporate advisory; Management buy ins/outs, Partnerships and LLPs; Sale and purchase agreements and Venture capital.
Chris Yates, CEO, Abingdon Health
Abingdon Health is a leading lateral flow rapid test developer and manufacturing. Chris co-founded Abingdon Health in 2008 and has been CEO since 2015. Abingdon floated on the AIM market of the London Stock Exchange in December 2020. Previously, Chris has held CFO roles at private-equity backed Nexus Vehicle Rental and two AIM-listed companies: Immunodiagnostic Systems and Cozart.